$41.60
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Country

NL

CEO

Mr. Thierry Bernard

IPO date

1996

Employees

5,654

ISIN

NL0015002SN0

Key stats

Open

$41.67

Volume

12.75M

Market cap

$7.83B

Prev. close

$41.99

Impl / hst vl

-

Open interest

$0.00

$41.07

Day’s Range

$42.17

$32.53

52W Range

$56.19

Valuation

55
Valuation score
Fairly Valued
P/E
19.44
P/S
3.73
P/B
2.35
Current ratio
3.21
Debt / Equity
0.30
ROE
11.28%
Gross margin
62.89%
Income growth
-36.90%
FCF growth
-55.26

Jul

14

Dividends

The last payment date was Jul 14, 2026

Div. per Share

$0.35

Div. Yield

0.92%

Payout Ratio

-

Div. Growth YoY

40.00%

Analysts estimates

Consensus rating
Hold

The average rating from top 11 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$45.34
The top 17 analysts forecasts that 12-month price may increase by 8.98%, with a low of $36.36 and a high of $64.05
$36.36
Low
$45.34
Avg
$64.05
High
Current price

Earnings

Q1 ‘26 revenue
$492.32M
Q1 ‘26 net income
$68.04M
Revenue
Net income
Previous EPS
$0.54
Estimate EPS
$0.61
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply